ReviewBiomaterials translational2025
Microneedles in biomedicine: Innovations, challenges, and future prospects.
Review in Biomaterials translational, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing biomedical innovation through composite material strategies.Biomaterials translational · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effective delivery of therapeutic drugs is fundamental to modern medical practice. However, conventional administration methods, primarily oral and parenteral injection, exhibit numerous limitations, including the suboptimal bioavailability of macromolecules and challenges related to patient compliance. The advent of microneedle (MN) technology is reshaping strategies in the biomedical field, effectively overcoming the constraints of traditional drug delivery and diagnostic approaches. Research indicates that MNs can penetrate the stratum corneum to form transient microchannels, facilitating the transdermal delivery of therapeutic agents while bypassing gastrointestinal and hepatic barriers. This customizable and personalized drug delivery system holds significant potential for clinical application. Beyond drug delivery, MNs also have the capacity to transform healthcare models through real-time biomarker monitoring enabled by contact with interstitial fluid. This technology demonstrates considerable promise in managing chronic conditions such as diabetes, while also opening avenues for applications in vaccination, tissue regeneration, and cancer therapy. Recent innovations include the development of stimulus-responsive MNs for precision medicine and their integration with wearable devices to achieve closed-loop therapeutic diagnostics. Despite the substantial promise of this field, challenges remain regarding clinical translation, particularly in relation to biocompatibility, mechanical strength, and drug stability. This review outlines MN classifications, design principles, and applications, emphasizing their expanding role not only in healthcare but also in precision medicine, global health, and food safety. By overcoming current barriers and integrating emerging technologies, MNs have the potential to transform diagnostic and therapeutic paradigms, delivering scalable, patient-centered solutions to a broad range of biomedical challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.